
Maya Koronyo, PhD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
310-423-7900

- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Maya Koronyo, PhD
Neurosurgery - Pavilion
127 S San Vicente Blvd #A6600
Los Angeles, CA
34.074522 -118.379067From You
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.

Maya Koronyo, PhD
Languages
- English,
- Hebrew,
Gender
Female
Experience
17 Years
Locations
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- Research
Programs
Research Areas
The lack of effective treatment for Alzheimer's disease (AD) has necessitated more accurate and earlier diagnostic tools as well as disease-modifying therapies. A major focus of the Koronyo-Hamaoui Lab is development of immune-modulation treatment approaches and the investigation of the role that innate immune cells, especially peripheral monocytes and macrophages, may play in CNS repair and regeneration. The team discovered that blood enrichment with bone marrow-derived CD115+ monocytes by adoptive transfer into the peripheral blood of transgenic murine models of AD, or immunization with altered myelin-derived antigens, led to marked attenuation of disease progression and preservation of cognitive function. These multifaceted immune modulation interventions were found to mobilize neuroprotective inflammatory myeloid cells to cerebral lesion sites, which effectively removed toxic metabolites including amyloid; beta- protein, regulated neuroinflammation (i.e. reduced alpha and elevated IL-10), and stimulated synaptogenesis and neurogenesis. Specific molecular mediators for the beneficial effects were further identified; among these are osteopontin (OPN; also called SPP1), the transcription factor early growth response protein 1 (Egr1; also known as NGFI-A), and insulin-like growth factor-1 (IGF-1). To enhance the capacity of these innate immune cells to resist AD pathology, the lab studied the effects of targeted over-expression of an Ab degrading enzyme, angiotensin-converting enzyme (ACE), to myelomonocytes in murine models of AD. Introduction of ACE overexpressing monocytes to blood circulation of AD-model mice resulted in substantial prevention of synaptic loss and cognitive decline as well as attenuation of AD-associated pathology including diminished vascular amyloidosis. Continued efforts concentrate on identification of novel therapeutic approaches through better understanding of immune-CNS interactions and innate-immune mechanisms of synaptic preservation involved in regulation of detrimental inflammation, clearance of pathogenic beta species, and tissue regeneration. Another major focus of the Koronyo-Hamaoui Lab has been to explore Alzheimer's-related pathological changes occurring in the neurosensory retina, an accessible CNS organ for noninvasive high-resolution live imaging. The Koronyo-Hamaoui team has identified and characterized for the first time ever the pathological hallmarks of AD, beta deposits, in retinas of human patients and in early stage cases. These findings have led the team to pioneer an innovative methodology of in vivo and noninvasive detection of retinal amyloid deposits by utilizing curcumin labeling. This noninvasive retinal beta plaque imaging was translated to humans and is currently being tested in multiple clinical trials. It has potential applications for earlier AD diagnosis and follow-up response to AD therapies. Currently, the team seeks to discover novel retinal biomarkers and compare them to brain pathology associated with AD. Recently, the team revealed an early and substantial apoptotic pericyte cell loss along with decreased vascular platelet-derived growth factor receptor-beta; (PDGFR beta;) expression that were associated with vascular amyloidosis in postmortem retinas from MCI and AD patients. These changes further correlated with cerebral pathology and cognitive status. These findings open up new questions related to Alzheimer's-related vascular pathology in the retina and the role of pericytes in clearance of retinal beta and AD pathogenesis.
Titles
- Professor, Biomedical Sciences
- Research Scientist, Maxine Dunitz Neurosurgical Institute
- Professor, Neurosurgery
Education & Training
-
Weizmann Institute of Science
Degrees - Completed 2006
-
Tel-Aviv University
Degrees - Completed 2005
-
Tel-Aviv University
Degrees - Completed 1998
-
Tel-Aviv University
Degrees - Completed 1995
Achievements
-
27
Awards and Honors
-
6
Publications
Awards and Honors
- Dean’s Excellence Award & Prize, the George S. Wise Life Sciences Faculty, Tel-Aviv University, Israel
- Founding Member, Inventor, Consultant, NeuroVision Imaging, Inc. (NVI)
- Pioneer in Medicine Award, Society for Brain Mapping Foundation on Retinal Amyloid Imaging in AD
- Invited Panelist & Speaker, Alzheimer’s Association AAIC-Sydney Satellite Symposium, Session: ‘Novel Biomarkers’
- Invited ARVO-Vancouver Moderator & Speaker, Basic/Clinical Session: ‘A window on the soul: How systemic disease manifests in the eye’
- Invited Panel Speaker, The Association for Research in Vision and Ophthalmology Conference in the Special Interest Group 'Ocular Biomarkers for Early Detection of AD'
- Editorial Board Member, Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (A&D: DADM)
- The BrightFocus Foundation, Alzheimer's Disease Research Award
- Coins for Alzheimer’s Research Trust (CART) Fund, Primary Research Award
- Guest Editor, Journal of Clinical Medicine (JCM) for the Special Issue “The Diagnosis of Dementia Due to Alzheimer's Disease”
- Executive Committee Member, an Alzheimer’s Association ISTAART committee for ‘Vascular Cognitive Disorders’ PIA
- NIH/NIA R01 AG055865
- NIA R01 AG056478-04S1
- Alzheimer’s Disease Research Center (ADRC) Summit Steering Committee, Neurology & Neurosurgery Departments
- Invited Organizer, Chair & Panel Speaker, SBMT/AD Conference
- ASNI board member, American Society of Neuroimmunology (ASNI) Seminar Series
- Invited Subcommittee Member & Speaker Panelist, ‘Think Tank’ Alzheimer’s Association Retinal Imaging in Alzheimer's & Neurodegenerative Diseases Workshop (RIAD)
- DNRCA Collaborative Research Award
- Mentor: Alzheimer’s Association Research Fellowship to Promote Diversity (AARF-D)
- Executive Committee Member, an Alzheimer’s Association ISTAART committee for ‘The Eye as Biomarker for Alzheimer's Disease’ PIA
- Editorial Board: Public Library of Science (PLoS and PLoSONE)
- Wolf Fund Excellence Award & Prize, Sackler School of Medicine Faculty Dean, Tel-Aviv University, Israel
- Lead Topic Editor, Frontiers in Immunology. Research Topic: Role of Inflammation in Neurodegenerative Diseases. Section: Multiple Sclerosis and Neuroimmunology
- Board of Directors & Scientific Committee Member, Society for Brain Mapping & Therapeutics
- NIH/NIA R01 AG056478
- Invited SfN Nanosymposium Co-Chair & Speaker, ‘Neurotoxicity, Inflammation, and Neuroprotection: Neuroinflammation: Neurodegeneration’ Session
- NIA R01 AG056478
Publications
A full list of this provider’s research publications can be found on their research profile or PubMed.
- Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, Blanco A, Fuchs DT, Ashfaq A, Frautschy S, Cole GM, Miller CA, Hinton DR, Verdooner SR, Black KL, Koronyo-Hamaoui M. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017;2(16):e93621. Featured in JCI This Month.
- Rentsendorj A, Sheyn J, Fuchs DT, Daley D, Salumbides BC, Schubloom HE, Hart NJ, Li S, Hayden EY, Teplow DB, Black KL, Koronyo Y, Koronyo-Hamaoui M. A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer's models. Brain Behavior and Immunity. 2018 (Published Online September 2017);67:163-180.
- Lahiri S, Regis GC, Koronyo Y, Fuchs D-T, Sheyn J, Kim E, Mastali M, Van Eyk J, Rajput PS, Lyden PD, Black KL, Ely EW, Jones H, Koronyo-Hamaoui M. Acute Neuropathological Consequences of Mechanical Ventilation in Wild-Type and Alzheimer’s Disease Mice. Critical Care. 2019;23(1):63.
- Koronyo-Hamaoui M, Sheyn J, Hayden EY, Li S, Fuchs DT, Regis GC, Lopes DHJ, Black KL, Bernstein KE, Teplow DB, et al. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain. 2019 pii: awz364.
- Li, S, Hayden, EY, Garcia, VJ, Fuchs D-T, Sheyn, J, Daley DA, Rentsendorj, A, Torbati, T, Black, KL, Rutishauser, U, Teplow, DB, Koronyo Y, Koronyo-Hamaoui, M. Activated Bone Marrow-derived Macrophages Eradicate Alzheimer’s-Related Aß42 Oligomers and Protect Synapses. Frontiers in Immunology. 2020; 11:49.
- Shi H, Koronyo Y, Rentsendorj A, Regis GC, Sheyn J, Fuchs DT, Kramerov AA, Ljubimov AV, Dumitrascu OM, Rodriguez AR, Barron E, Hinton DR, Black KL, Miller CA, Mirzaei N, Koronyo-Hamaoui M. Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathologica. 2020.